| Drug ID: | Drug193 |
|---|---|
| Drug Name: | Olsalazine |
| CID: | 22419 |
| DrugBank ID: | DB01250 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT00004288 |
| Molecular Formula: | C14H10N2O6 |
| Molecular Weight: | 302.24 g/mol |
| Isomeric SMILES: | C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O |
| Synonyms: | Olsalazine; 15722-48-2; Olsalazina; Olsalazinum; 5,5'-Azobis(salicylic acid); C. i. mordant yellow 5; 5,5'-azodisalicylic acid; ULS5I8J03O; Benzoic acid, 3,3'-azobis(6-hydroxy-; Azodisal |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 1 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Mesalamine works as an anti-inflammatory agent in treating inflammatory diseases of the intestines. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1353 | 22419 | Olsalazine | 5742 | PTGS1 | Homo sapiens (human) | 12950415 | Inhibitor |
| dt1354 | 22419 | Olsalazine | 5743 | PTGS2 | Homo sapiens (human) | 12950415 | Inhibitor |
| dt1355 | 22419 | Olsalazine | 7172 | TPMT | Homo sapiens (human) | Inhibitor | |
| dt1356 | 22419 | Olsalazine | 7498 | XDH | Homo sapiens (human) | 3067340 | Inhibitor |
| dt1357 | 22419 | Olsalazine | 56606 | SLC2A9 | Homo sapiens (human) | 32863294 | Downregulator |
| dt1358 | 22419 | Olsalazine | 9356 | SLC22A6 | Homo sapiens (human) | 32863294 | Upregulator |
| dt1359 | 22419 | Olsalazine | 9376 | SLC22A8 | Homo sapiens (human) | 32863294 | Upregulator |
| dt1360 | 22419 | Olsalazine | 6574 | SLC20A1 | Homo sapiens (human) | 32863294 | Upregulator |
| dt1361 | 22419 | Olsalazine | 476 | ATP1A1 | Homo sapiens (human) | Inhibitor | |
| dt1362 | 22419 | Olsalazine | 477 | ATP1A2 | Homo sapiens (human) | Inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05707429 | Sexual Function and Quality of Life Among Patients Suffering From Inflammatory Bowel Disease(Inactive Stage) | NULL | COMPLETED | Assiut University | Sexual Function Disturbances|Inflammatory Bowel D… | OTHER: The Arabic version of The International In… | Details |
| NCT05701501 | Clinical Study of Vitamin B5 in Adjuvant Treatment of IBD | NA | UNKNOWN | Changhai Hospital | Inflammatory Bowel Diseases | DRUG: Vitamin B5 Tablets|DRUG: placebo | Details |
| NCT05688852 | VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease | PHASE2 | TERMINATED | Ventyx Biosciences, Inc | Crohn Disease | DRUG: VTX958|DRUG: VTX958|DRUG: VTX958 Placebo | Details |
| NCT05687474 | Baby Detect : Genomic Newborn Screening | NULL | COMPLETED | Centre Hospitalier Universitaire de Liege | Congenital Adrenal Hyperplasia|Familial Hyperinsu… | None | Details |
| NCT05684484 | Role of Roflumilast in Ulcerative Colitis | PHASE4 | COMPLETED | Tanta University | Ulcerative Colitis | DRUG: Roflumilast 500 MCG Oral Tablet [DALIRESP]|… | Details |
| NCT05668013 | A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease | PHASE2 | ACTIVE_NOT_RECRUITING | Teva Branded Pharmaceutical Products R&D LLC | Crohn Disease|Colitis, Ulcerative | DRUG: TEV-48574 Dose Regimen A|DRUG: TEV-48574 Do… | Details |
| NCT05666960 | R-3750 in Patients With Mild to Moderate Ulcerative Colitis | PHASE1 | RECRUITING | Rise Therapeutics LLC | Ulcerative Colitis Chronic Mild|Ulcerative Coliti… | DRUG: R-3750 | Details |
| NCT05663671 | Evaluate Established Anti-DEFA5 mAbs Diagnostic Efficacy and Safety in IBD | NULL | UNKNOWN | Meharry Medical College | Inflammatory Bowel Diseases|Ulcerative Colitis|Cr… | DIAGNOSTIC_TEST: Diagnostic Test | Details |
| NCT05659953 | LMT503 First-in-human SAD, MAD, and FE Study | PHASE1 | NOT_YET_RECRUITING | Lmito Therapeutics Inc. | Inflammatory Bowel Disease|Colitis, Ulcerative|Cr… | DRUG: LMT503|DRUG: Placebo | Details |
| NCT05643534 | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years | PHASE3 | RECRUITING | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | DRUG: Tenapanor 50 MG|DRUG: Tenapanor 25 mg bid|D… | Details |
| NCT05638347 | A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect. | PHASE1 | COMPLETED | Atridia Pty Ltd. | Inflammatory Bowel Disease | DRUG: HRS-7085 tablets|DRUG: Placebo tablet | Details |
| NCT05624801 | Cholecalciferol Comedication in Patients With Chronic Inflammatory Bowel Diseases (Crohn's Disease or Ulcerative Colitis) - the 5C-study | PHASE3 | Recruiting | University Hospital, Basel, Switzerland | IBD | Drug: D3 VitaCaps | Details |
| NCT07168434 | Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome | PHASE3 | RECRUITING | Biocodex | IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… | DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… | Details |
| NCT05611671 | A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC | PHASE2 | ACTIVE_NOT_RECRUITING | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | Inflammatory Bowel Diseases|Colitis, Ulcerative | DRUG: MORF-057|DRUG: Placebo | Details |
| NCT05549323 | A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis | PHASE1 | TERMINATED | Pfizer | Ulcerative Colitis | DRUG: PF-07054894|DRUG: Placebo | Details |
| NCT07161297 | Remimazolam for Colonoscopy in IBD Patients | PHASE4 | NOT_YET_RECRUITING | Humanitas Clinical and Research Center | IBD (Inflammatory Bowel Disease) | DRUG: Intravenous remimazolam (5 mg initially, wi… | Details |
| NCT05499130 | A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease | PHASE2 | COMPLETED | Teva Branded Pharmaceutical Products R&D, Inc. | Crohn Disease|Colitis, Ulcerative | DRUG: TEV-48574|DRUG: Placebo | Details |
| NCT05486104 | Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis | PHASE2 | ACTIVE_NOT_RECRUITING | Ganzhou Hemay Pharmaceutical Co., Ltd | Moderate to Severe Ulcerative Colitis | DRUG: Hemay005 tablets|DRUG: Hemay005 placebo tab… | Details |
| NCT07156929 | Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation | NA | COMPLETED | University Hospital Schleswig-Holstein | Respiratory Infection (for Example, Pneumonia, Br… | DIETARY_SUPPLEMENT: Controlled-ileocolonic-releas… | Details |
| NCT05471492 | Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease | PHASE2 | WITHDRAWN | Telavant, Inc. | Crohn Disease | DRUG: Investigational Product|DRUG: Placebo | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
An Olsalazine-Loaded Hollow Mesoporous Prussian Blue/Polydopamine Nanozyme Alle…
PMID: 40699132
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Individuals diagnosed with inflammatory bowel disease (IBD) exhibit a markedly elevated prevalence of psychiatric disorders, particularly anxiety and…
Oral olsalazine/ellagic acid/ZnCl(2)-modified in situ-forming hydrogels allevia…
PMID: 40688678
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a kind of chronic non-specific intestinal inflammatory disease, which accompanied by various abnormal psychologic…
An olsalazine nanoneedle-embedded inulin hydrogel reshapes intestinal homeostas…
PMID: 38024237
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a chronic and refractory condition characterized by disrupted epithelial barrier, dysregulated immune balance, an…
The effect of olsalazine of chinese generic drugs on ulcerative colitis induced…
PMID: 37610966
Year: 2023
Relationship Type:
Treatment
Score: 6.5
PURPOSE: To explore effect and mechanism of olsalazine of Chinese generic drugs on ulcerative colitis induced by dextran sulfate sodium salt (DSS) in…
Orally Administrated Olsalazine-Loaded Multilayer Pectin/Chitosan/Alginate Comp…
PMID: 37068182
Year: 2023
Relationship Type:
Treatment
Score: 6.5
The pathogenesis of inflammatory bowel diseases (IBDs) including ulcerative colitis (UC) and Crohn's disease is extremely cloudy. Maintaining the lev…
Copper-olsalazine metal-organic frameworks as a nanocatalyst and epigenetic mod…
PMID: 36087871
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Despite the extensive explorations of nanoscale metal-organic frameworks (nanoMOFs) in drug delivery, the intrinsic bioactivity of nanoMOFs, such as …
Pharmacokinetic and gut microbiota analyses revealed the effect of Lactobacillu…
PMID: 35697287
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Olsalazine is a typical 5-aminosalicylic acid (5-ASA) drug that depends on gut microbiota to liberate its anti-inflammatory moiety 5-ASA in the treat…
Technetium-99 m labeling and evaluation of olsalazine: a novel agent for ulcera…
PMID: 26031480
Year: 2015
Relationship Type:
Association
Score: 6.3
Ulcerative colitis is a chronic disease having a regressive nature. Commonly used diagnostic methods have the disadvantage to be invasive, time-consu…